Key result
Beta-blockers reduce mortality in the secondary prevention of ischemic heart disease and are highly efficient as antianginal medications, especially when administered within 12 hours of pain onset.
Why the study?
Do beta-blockers reduce mortality in the secondary prevention of ischemic heart disease?
Do beta-blockers reduce mortality in the secondary prevention of ischemic heart disease?
This review affirms that early and continued use of beta-blockers reduces mortality and ischemia in patients with ischemic heart disease.
Affirms beta-blocker benefits in IHD secondary prevention; leaves open need for contemporary RCTs.
Convincing evidence of the decline of mortality has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. The beta-blockers are also the most efficient antianginal medications for the decrease of ischemia in outpatients. They are highly efficient as a monotherapy for angina and are also a medication of choice for angina after the coronary. The objective of this work was an estimate of the use of beta-blockers in secondary prevention of the ischemic heart disease and eliminating doubts concerning their prescription. The method of the analysis sums up the results of a twenty-five-year study on of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease. The method of the work implies an examination of the professional literature and the data-bases, such as MEDLINE, Pub-Med and KOBSON. The first studies concerned non-selective beta-blockers, used orally. The following studies concerned cardioselective beta-blockers, metoprolol and atenolol. Several studies followed also the effect of beta-blockers and heparin, or beta-blockers and antagonists of calcium towards placebo, in patients with an unstable angina pectoris. Beta-blockers are an essential drug in secondary prevention of the myocardial infarction and in chronic heart failure. The necessary condition for the efficiency of beta-blockers is an early use. Beta-blockers should be given within 12 hours after the appearance of pain. The continuation of the therapy with beta-blockers after the acute phase is considered to be important in the decrease of the infarction zone expansion. Prophylactic use of beta-blockers after the coronary has an excellent effect, above all in patients with a minor, uncomplicated coronary. Though certain groups of beta-blockers have some special characteristics, when it comes to the treatment of angina pectoris, all beta-blockers are efficient. Generally, patients react well to them. Preference is given to cardioselective remedies, in patients with diabetes or lung disease. Exhaustive controlled clinical studies affirm beta-blockers as drugs that reduce mortality in secondary prevention of the ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Vesna Radović (2009) conducted a review in Ischemic heart disease. Beta-blockers was evaluated. Beta-blockers reduce mortality in the secondary prevention of ischemic heart disease and are highly efficient as antianginal medications, especially when administered within 12 hours of pain onset.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: